Nasopharyngeal Streptococcus Pneumoniae Carriage
An Evaluation of Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Taiwanese Children Attending Pediatric Clinics in Hospitals, Day Care Centers, or Kindergartens
Primary Objective: Evaluation of the
- Carriage rate of Streptococcus pneumoniae in the nasopharynx of children
Secondary Objective:
- Carriage rate and distribution of Streptococcus pneumoniae serotypes
- Estimation of prevalence rate of antibiotic-resistant Streptococcus pneumoniae strains
- Distribution of Staphylococcus aureus strain
- The influence of risk factors in the Streptococcus pneumoniae carriage rate in children
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Taoyuan, Taiwan, 333
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children aged between 2 months and 5 years attending pediatric clinics in hospitals, day care centers or kindergartens.
- Informed consent obtained from parents or legal guardian.
Exclusion Criteria:
- Children younger than 2 months of age.
- Children with following serious diseases: immunological disease, neoplastic disease, renal, cardiac or hematological disease, bronchodysplasia, Down's syndrome.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx
Time Frame: Day 1
|
Swab cultures obtained from the nasopharynx of participants were tested for the presence of streptococcus pneumoniae strains.
|
Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serotype Distribution of Streptococcus Pneumoniae Isolates
Time Frame: Day 1
|
Streptococcus pneumoniae in swab culture of nasopharynx were serotyped.
The assessment included 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F, non-vaccine, non-typable and missing serotypes.
Percentage of participants under different vaccine serotypes in identified isolates of streptococcus pneumonia are reported.
|
Day 1
|
|
Antibiotic-Resistant Streptococcus Pneumoniae Strains
Time Frame: Day 1
|
Antibiotic resistance is defined as in vitro inhibition of a particular bacterial strain by a concentration of the drug associated with high likelihood of therapeutic failure.
Antibiotic resistance for streptococcus pneumoniae was assessed against Penicillin, Cefotaxime, Levofloxacin, Erythromycin and combination of Trimethoprim with sulfamethoxazole.
The standard breakpoint value (microbial growth inhibition zone) for Penicillin, Cefotaxime, Levofloxacin, Erythromycin and combination of Trimethoprim with sulfamethoxazole was not more than 8, 4, 13, 15 and 15 millimeter (mm) respectively.
Percentage of participants with antibiotic-resistant streptococcus pneumoniae strains are reported.
The same participant may have streptococcus pneumoniae strains which is resistance to more than one antibiotic.
|
Day 1
|
|
Percentage of Participants With Carriage of Staphylococcus Aureus in Nostril
Time Frame: Day 1
|
Swab cultures obtained from the nostril of participants were tested for the presence of Staphylococcus aureus strains.
|
Day 1
|
|
Percentage of Participants With Carriage of Streptococcus Pneumoniae Based on Risk Factors
Time Frame: Day 1
|
Participants for carriage of streptococcus pneumoniae were analyzed with respect to various risk factors which included number of bathrooms, number of siblings in the family (multiple siblings), size of the house in meter square (house area), frequency of hand wash in a day, bed sharing, smoking by family member, child breast feeding (breast milk practice), daycare attendance, vaccination for flu and pneumococcus, history of otitis media and upper respiratory infection (URI), antibiotic use and influenza virus infection.
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0887X-101849
- B1841034
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.